Citations

Clear

479 citation(s) found for "Tobias, JS".

Comparative Cost-effectiveness of Surgery, Collagenase Clostridium Histolyticum, and Penile Traction Therapy in Men with Peyronie’s Disease in an Era of Effective Clinical Treatment
Wymer, Kevin , Köhler, Tobias , Trost, Landon

Mayo Clinic

The Journal of Sexual Medicine | July 24, 2019 | Volume: 16 | Issue: 9 | Pages: 1421-1432

10.1016/j.jsxm.2019.06.010 | PMID 31351851 Get It

ABSTRACT Background Traditionally, surgery has been considered the gold standard treatment for Peyronie’s disease (PD). Less-invasive alternatives, such as collagenase Clostridium histolyticum (CCH) and traction therapy, have been proposed and proven effective. Aim To compare cost-effectiveness of management options for PD. Methods A Markov analytic model was created to compare the cost-effectiveness of treatment with a novel traction device, RestoreX (RXPTT), vs CCH vs surgery. Outcomes were derived from single-institution, prospective data of 63 men treated with RXPTT, 115 with CCH, and 23 with plication or incision and grafting. Costs were based on 2017 Medicare reimbursement and utility values from the literature. Main Outcome Measures Model outcomes included complications for each treatment arm, as well as the probability of success, which was defined as ≥20% improvement in curvature. Univariable and multivariable sensitivity analyses were performed to test the robustness of the model. Results Overall success rates were 96% (surgery), 66% (CCH), and 48% (RXPTT). At 10 years after treatment, RXPTT was the most cost-effective, with mean costs per patient of $883 (RXPTT), $11,419 (surgery), and $33,628 (CCH). CCH and surgery both resulted in a gain of quality adjusted life years (QALYs) relative to RXPTT (9.44 and 9.36 vs 9.27, respectively). Sensitivity analysis demonstrated greater cost-effectiveness for surgery if lower (≤46%) rates of postoperative erectile dysfunction or length loss (≤3%). CCH became more cost-effective at lower costs (≤$16,726) or higher success rates (≥76%). On multivariable sensitivity analysis at a willingness to pay threshold of $100,000/QALY, the most cost-effective strategy was RXPTT in 49%, surgery in 48%, and CCH in 3% of simulations. At a willingness to treat threshold of $150,000/QALY, the most cost-effective treatment option was RXPTT in 33%, surgery in 55%, and CCH in 12% of simulations. Clinical Implications In an era of value-based care, this model can guide cost-effective treatment selection on the basis of provider, patient, and payer characteristics. Strengths & Limitations The current study represents the first cost-effectiveness comparison of treatment modalities for PD and is strengthened by prospective data collection, large CCH and traction sample sizes, and robust sensitivity analyses. Consistent with cost-effective models, the model is limited by assumptions and may not apply to all scenarios. Conclusions RXPTT represents a more cost-effective method for achieving ≥20% curvature improvement compared with surgery or CCH. Depending on treatment goals, rate of surgical complications, and willingness to pay threshold, surgery and CCH may become more cost-effective in select scenarios.
A phase II single-arm study of CRS-207 with pembrolizumab (pembro) in previously treated malignant pleural mesothelioma (MPM).
Alley, Evan , Jahan, Thierry, Peikert, Tobias, Stevenson, James, Schlienger, Katia, Liu, Weiqun , Honarmand, Somayeh, Kindler, Hedy L. , Tanvetyanon, Tawee , Gandhi, Leena , Nair, Nitya

Mayo Clinic

Journal of Clinical Oncology | July 11, 2019 | Volume: 37 | Issue: 8_suppl | Pages: 29-29

10.1200/jco.2019.37.8_suppl.29 Get It

29 Background: CRS-207 is a live, attenuated, double-deleted Listeria monocytogenes (LADD) engineered to stimulate immune response to mesothelin. In a phase I trial of 60 MPM patients, 34% of subjects had tumor reduction (range -1 to -47%) following 2 doses of CRS-207 alone. In KEYNOTE-028 pembro showed activity in PDL1+ (≥1% by IHC) MPM, with an objective response rate (ORR) of 20% (5/25) and stable disease in 52% of subjects who had failed or did not receive chemotherapy. Subsequent studies of pembro have shown similar results in MPM. Results from a pre-clinical murine lung tumor model (CT26hMeso) showed anti-PD-1 enhanced LADD-induced tumor response. The study described here evaluated the efficacy of combination therapy of CRS-207/pembro. Methods: Adults with epithelial/biphasic MPM, ≤2 prior lines, progression on pemetrexed and platinum-based therapy, and no prior immunotherapies were enrolled. CRS-207/pembro were administered IV Q3W for 4 cycles, after which pembro continued Q3W and CRS-207 changed to Q6W. Response was assessed Q6W by modified RECIST for MPM (Byrne and Nowak, 2004). The primary endpoint was ORR; secondary endpoints included DOR, disease control rate (DCR), progression-free survival (PFS) and overall survival. Pre- and on-treatment blood and tumor samples were collected. Shedding and blood clearance of CRS-207 were evaluated. Results: 9/10 subjects were evaluable for response. No responses were observed; DCR was 11% (1/9 with SD) and PFS ranged from 3.4 to 8.9 weeks. Most common treatment related adverse events were chills, pyrexia and nausea. 3/10 subjects evaluated were PDL-1 negative by IHC. Of 6 subjects who underwent clearance and shedding evaluation, CRS-207 was detected in blood in 1 at 18-24 hrs after the first CRS-207 dose and cleared by the next evaluation at Day 4; shedding samples (urine, fecal, and saliva) tested negative. Conclusions: The toxicity profile of CRS-207/pembro combination was consistent with the safety profile of each component alone. No evidence of clinical activity was observed. Based on the results and an overall evaluation of the program, the clinical development of CRS-207 was discontinued. (NCT01675765) (NCT02054806). Clinical trial information: NCT03175172.
Multicenter Investigation of Fungal Infections of Inflatable Penile Prostheses
Gross, Martin , Reinstatler, Lael , Henry, Gérard , Honig, Stanton, Stahl, Peter J., Maria, Pedro , Bennett, Nelson , Kava, Bruce, Köhler, Tobias , Beilan, Jonathan , Carrión, Rafael , Munarriz, Ricardo , Burnett, Arthur L. “Bud”

Mayo Clinic

The Journal of Sexual Medicine | June 26, 2019 | Volume: 16 | Issue: 7 | Pages: 1100-1105

10.1016/j.jsxm.2019.05.003 | PMID 31255212 Get It

Abstract Background Fungal infections of inflatable penile prostheses (IPPs) are inadequately understood in the literature. Aim To review a multi-institution database of IPP infections to examine for common patient and surgical factors related to IPP fungal infections. Methods This is a retrospective Institutional Review Board–approved analysis of 217 patients at 26 institutions who underwent salvage or device explant between 2001 and 2018. Patient data were compiled after an extensive record review. Outcomes 26 patients (12%) with fungal infections were identified. Results 23 of 26 patients (83%) with a fungal IPP infection were either diabetic or overweight. 15 patients had undergone primary IPP implantation, and the other 11 had previously undergone an average of 1.7 IPP-related surgeries (range 1–3; median 2). The average age at implantation was 63 years (range 31–92; median 63). 18 of the 26 patients with fungal infection had diabetes (69%), with a mean hemoglobin A1c (HbA1c) value of 8.4 (range 5.8–13.3; median 7.5). Twenty-two patients (85%) were overweight or obese. The mean body mass index for all patients was 30.1 kg/m2 (range 23.7–45 kg/m2; median 28.4 kg/m2), and that for diabetic patients was 30.8 kg/m2 (range 24.1–45 kg/m2, median 29.7 kg/m2). Ninety-one percent of implants were placed with intravenous antibiotics, consistent with current American Urological Association guidelines: an aminoglycoside plus first- or second-generation cephalosporin or vancomycin or ampicillin/sulbactam or piperacillin/tazobactam. 65% (17 of 26) of infected IPPs had only fungal growth in culture. No patient had concomitant immunosuppressive disease or recent antibiotic exposure before IPP implantation. Clinical Implications More than two-thirds of the fungal infections occurred in diabetic patients and 85% occurred in overweight or obese patients, suggesting that antifungal prophylaxis may be appropriate in these patients. Strengths & Limitations This is the largest series of fungal infections reported to date in the penile prosthesis literature. The overall number of such cases, however, remains small. Conclusion Fungal infections represent 12% of all penile prosthesis infections in our series and were seen mostly in diabetic or overweight patients, who may benefit from antifungal prophylaxis.
Electroencephalographic Reporting for Refractory Status Epilepticus
Sansevere, Arnold J. , Fernández, Iván Sánchez , Gaillard, William D. , Tasker, Robert C. , Lai, Yi‐Chen , Anderson, Anne E. , Tchapyjnikov, Dmitry , Chapman, Kevin , Brenton, J. Nicholas , Carpenter, Jessica L. , Gaínza‐Lein, Marina , Goldstein, Joshua , Goodkin, Howard P. , Jackson, Michele , Mikati, Mohamad A. , Peariso, Katrina , Topjian, Alexis , Wainwright, Mark S. , Williams, Korwyn, Loddenkemper, Tobias , Wilfong, Angus A. , Williams, Korwyn L, Brenton, J Nicholas , Tasker, Robert C , Tchapyjnikov, Dmitry , Wainwright, Mark S , Lai, Yi-Chen , Gaillard, William D , Mikati, Mohamad A , Loddenkemper, Tobias , Arya, Ravindra , Kapur, Kush , Glauser, Tracy A. , Abend, Nicholas S.

Mayo Clinic

Journal of Clinical Neurophysiology | June 5, 2019 | Volume: 36 | Issue: 5 | Pages: 365-370

10.1097/wnp.0000000000000595 | PMID 31166226 Get It

Purpose: We aimed to determine whether clinical EEG reports obtained from children in the intensive care unit with refractory status epilepticus could provide data for comparative effectiveness research studies. Methods: We conducted a retrospective descriptive study to assess the documentation of key variables within clinical continuous EEG monitoring reports based on the American Clinical Neurophysiology Society's standardized EEG terminology for children with refractory status epilepticus from 10 academic centers. Two pediatric electroencephalographers reviewed the EEG reports. We compared reports generated using free text or templates. Results: We reviewed 191 EEG reports. Agreement between the electroencephalographers regarding whether a variable was described in the report ranged from fair to very good. The presence of electrographic seizures (ES) was documented in 46% (87/191) of reports, and these reports documented the time of first ES in 64% (56/87), ES duration in 72% (63/85), and ES frequency in 68% (59/87). Reactivity was documented in 16% (31/191) of reports, and it was more often documented in template than in free-text reports (40% vs. 14%, P = 0.006). Other variables were not differentially reported in template versus free-text reports. Conclusions: Many key EEG features are not documented consistently in clinical continuous EEG monitoring reports, including ES characteristics and reactivity assessment. Standardization may be needed for clinical EEG reports to provide informative data for large multicenter observational studies.
Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis
Larsen, Brandon T. , Chae, June, Dixit, Anuj , Hartman, Thomas E. , Peikert, Tobias, Roden, Anja C.

Mayo Clinic

American Journal of Surgical Pathology | June 3, 2019 | Volume: 43 | Issue: 10 | Pages: 1331-1340

10.1097/pas.0000000000001298 | PMID 31162288 Get It

Immune checkpoint inhibitors (ICIs) have revolutionized oncology, but are associated with immune-related adverse events. Clinically, pneumonitis is a well-recognized complication, but its histopathologic features are poorly understood. Institutional archives were searched for patients having ICI therapy and subsequent lung tissue sampling. After excluding infectious cases, 9 patients (5 women, median: 59 y) were identified with clinically suspected ICI-related pneumonitis. Clinical history, imaging, and pathology slides were reviewed. Patients received pembrolizumab (6 cases), nivolumab (1), ipilimumab followed by pembrolizumab (1), or pembrolizumab followed by nivolumab (1); the latter experienced pneumonitis with both agents. Treatment duration ranged from 1 to 33 cycles (median: 8). Three patients received concurrent chemotherapy and 1 received radiation; the remainder received ICI monotherapy. Symptoms were nonspecific; 2 patients were asymptomatic. Thoracic imaging showed bilateral ground glass or nodular opacities in all cases, often with pleural effusion. Histologically, organizing pneumonia was seen in 7 patients, all with subclinical or mild disease, admixed with vague non-necrotizing airspace granulomas in 3 cases; all 6 patients with follow-up did well. One patient had acute fibrinous pneumonitis and 1 had diffuse alveolar damage; both died. All 9 cases showed foamy macrophages and pneumocyte vacuolization; 6 had rare eosinophils. ICI-related pneumonitis presents as bilateral ground-glass opacities or nodules, and usually manifests as organizing pneumonia histopathologically, often with vague non-necrotizing airspace granulomas. Foamy macrophages and pneumocyte vacuolization are characteristic and rare eosinophils are often seen. Less commonly, acute fibrinous pneumonitis or diffuse alveolar damage can occur, which may be fatal.
Efficacy of Combined Collagenase Clostridium histolyticum and RestoreX Penile Traction Therapy in Men with Peyronie’s Disease
Alom, Manaf, Sharma, Kiran , Toussi, Amir , Köhler, Tobias , Trost, Landon , Sharma, Kiran L

Mayo Clinic

The Journal of Sexual Medicine | April 4, 2019 | Volume: 16 | Issue: 6 | Pages: 891-900

10.1016/j.jsxm.2019.03.007 | PMID 30956106 Get It

ABSTRACT Background Previous studies of penile traction therapy (PTT) devices have demonstrated limited/no efficacy when combined with intralesional therapies for Peyronie’s disease (PD). Recently, randomized data have demonstrated the efficacy of a novel PTT device, RestoreX, developed in cooperation with the Mayo Clinic, in men with PD. Aim To assess the safety and efficacy of treatment with the RestoreX device plus collagenase Clostridium histolyticum (CCH) compared with CCH alone and CCH with other PTT devices. Methods A prospective registry has been maintained of all men undergoing CCH injections for PD between March 2014 and January 2019. Assessments were performed at baseline, during each series, and after completion of treatment. Those completing therapy (8 injections or sooner if satisfied) were categorized into group 1 (CCH alone), group 2 (CCH plus any PTT device other than RestoreX), or group 3 (CCH plus RestoreX). Outcomes Changes in penile length, curvature, and subjective perception and the occurrence of adverse events. Results Of 287 men with data on PTT use, 113 had completed therapy with all objective data available and compose the current cohort. Baseline demographic and pathophysiological variables were similar among the 3 groups except penile length and previous PD medications. Following treatment, group 3 demonstrated significantly greater improvements in curvature (mean, 20.3°/31% for group 1, 19.2°/30% for group 2, and 33.8°/49% for group 3), length (-0.7 cm/-4%, -0.4 cm/-2%, and +1.9 cm/+17%, respectively), and subjectively estimated curvature improvement (44%, 32%, and 63% respectively), despite shorter daily PTT use (0.9 vs 1.9 hours/day). Group 3 was more likely than the other groups to experience ≥20°, ≥20%, and ≥50% curvature improvements, ≥1 cm length gain, and ≥20% length improvement. All results were statistically significant for group 3 versus groups 1 and 2, but not between groups 1 and 2, even after controlling for baseline features and isolating a subset of ≥3 hours/day PTT use (group 2). Group 3 was 6.9 times more likely to achieve ≥20° curvature improvement, and 3.5 times more likely to achieve ≥50% curvature improvement, and 10.7 times more likely to experience ≥20% length improvement. Adverse events were similar among the 3 groups. Clinical Implications Use of the RestoreX device enhances mean curvature outcomes by 71% and increases penile length in men with PD receiving CCH therapy. Strengths & Limitations Study strengths include a prospective registry, consistent assessments, the largest single-site series with complete posttreatment outcomes reported to date, the largest PTT series reported to date, and a true-to-life clinical design. Limitations include the nonrandomized methodology and single-site setting. Conclusion The combination of RestoreX and CCH is associated with significantly greater curvature and length improvements compared with CCH alone or CCH with other PTT devices.
299 Intra-operative Use of Betadine Is Associated with an Increased Rate of Penile Prosthesis Infections
Manka, Madeleine, Dodge, Nicole, Köhler, Tobias , Trost, Landon , Hebert, Kevin

Mayo Clinic

The Journal of Sexual Medicine | March 29, 2019 | Volume: 16 | Issue: Supplement_1 | Pages: S141-S141

10.1016/j.jsxm.2019.01.301 Get It

245 Rezūm Prostate Ablation for Large Gland (≥80 grams) Prostates
Avant, R., Gopalakrishna, A., Andrews, Jack R. , Alom, Mulham , Köhler, Tobias , Yang, David Y. , Hebert, Kevin , Gopalakrishna, A., Helo, Sevann

Mayo Clinic

The Journal of Sexual Medicine | March 29, 2019 | Volume: 16 | Issue: Supplement_1 | Pages: S117-S118

10.1016/j.jsxm.2019.01.251 Get It

170 6-month Outcomes of RestoreX Penile Traction Therapy in Men with Peyronie's Disease: A Randomized, Controlled Trial
Joseph, Jonathan, Ziegelmann, M., Meng, Yufei , Köhler, Tobias , Trost, L., Savage, Joshua S.

Mayo Clinic

The Journal of Sexual Medicine | March 29, 2019 | Volume: 16 | Issue: Supplement_1 | Pages: S86-S86

10.1016/j.jsxm.2019.01.179 Get It

113 Long-term Complete Outcomes of Concurrent Tachosil Grafting with Inflatable Penile Prosthesis Placement
Ring, Joshua , Patel, Neil , Wymer, Kevin , Hatzichristodoulou, Georgios , Köhler, Tobias , Gupta, N.

Mayo Clinic

The Journal of Sexual Medicine | March 29, 2019 | Volume: 16 | Issue: Supplement_1 | Pages: S58-S58

10.1016/j.jsxm.2019.01.123 Get It